Filing Details

Accession Number:
0001415889-24-019600
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-16 17:37:02
Reporting Period:
2024-07-12
Accepted Time:
2024-07-16 17:37:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1967163 Anish Patel C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-07-12 17,475 $25.07 376,552 No 4 S Indirect See footnote
Common Stock Disposition 2024-07-15 30,978 $25.05 345,574 No 4 S Indirect See footnote
Common Stock Disposition 2024-07-16 1,547 $25.01 344,027 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
  2. This transaction was executed in multiple trades at prices ranging from $25.00 to $25.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the Reporting Person serves as trustee.
  4. This transaction was executed in multiple trades at prices ranging from $25.00 to $25.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. This transaction was executed in multiple trades at prices ranging from $25.00 to $25.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.